Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Trial Profile

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary) ; NKTR-262 (Primary)
  • Indications Breast cancer; Carcinoma; Colorectal cancer; Malignant melanoma; Merkel cell carcinoma; Ovarian cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REVEAL
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 21 Dec 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2023.
    • 21 Dec 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2020.
    • 23 Oct 2018 Trial design of the study assessing efficacy and safety presented at the 43rd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top